The glucocorticoid receptor (GR) is a ligand-regulated transcription factor whose ability to bind hormone is thought to be dependent on association with the 90-kDa heat shock protein (hsp90). In the present study, we have generated a novel form of the GR, in which the receptor remains complexed to hsp90 but has lost its ability to bind hormone, the amount of GR-bound hsp90 was also unaltered in response to POBA. Taken together, the above observations provide evidence for a novel state of the GR within intact cells in which hsp90 interaction is but one step in the generation or maintenance of hormone-competent receptors.
In addition, these results point to the potential use of POBA, and possibly other CaM inhibitors, as antagonists of steroid receptor actions. (Molecular
INTRODUCTION
The signal transduction pathway of steroid hormones can be divided into two major stages based on the functional state of the receptor protein. In the untransformed state, steroid receptors exist as large heteromerit complexes containing one molecule of receptor and two molecules of 90-kDa heat shock protein (hsp90); the accumulated evidence suggests that the receptor in this complex is fully competent for hormone-binding function (see Refs. 1 and 2 for review). In the transformed state, steroid receptors have dissociated from hsp90 in response to hormone and are able to bind DNA and enhance specific gene expression (1, 2) . Thus, hsp90 appears to be a central component in the signal pathway of steroid hormones.
With regard to the glucocor-ticoid receptor (GR) incubation for an additional 20 h. As an initial step in identifying the stage of the GR signal pathway affected by these antagonists, we tested the idea that POBA may be acting by inhibiting hormoneinduced transformation of the GR. In the experiments shown in Fig. 1 hormone treatment. These results suggest that the inhibitory effect of POBA occurs primarily during the transformation process and not at the level of transcription, translation, or protein (CAT) stability. As a further test of the above hypothesis, we mea- The results presented in Figs. 1 and 2 suggest that the inhibitory effect of POBA on the GR occurs at a stage before the activation of transcriptional enhancement activity. One way in which this could happen is by preventing the nuclear translocation and/or DNAbinding functions of the GR. We have tested this possibility by measuring the amounts of cytosolic and nuclear GR in cells treated with various combinations of Dex and POBA (Fig. 3) . The results show a POBA concentration-dependent decrease in Dex-induced nuclear translocation of the GR.
POBA Inhibition of GR Transactivation Results from Loss of Hormone-Binding Function
Although the findings presented in Fig. 3 implicate the translocation process as a potential target stage for the effects of POBA, it remained possible that an effect of POBA on GR hormone-binding function could have the same result. For this reason, we performed the (25), it is likely that the primary effect of these CaM antagonists on the GR signal pathway is to inhibit the ability of GR to bind hormone.
As it is well known that reduced sulfhydryl groups are required for a variety of GR functions, including steroid-binding activity (27), and that an endogenous NADPH-dependent, thioredoxin-mediated, thiol-disulfide exchange system exists that is responsible for maintaining the rat liver GR in the steroid-binding state (28), we tested the possibility that the inhibitory effect of POBA on GR steroid-binding function was the result of sulfhydryl group oxidation.
In the experiments shown in Fig. 4B , LMCAT cells were treated with POBA, and cytosols were prepared in the presence or absence of dithiothreitol (DlT), an agent capable of reducing disulfide bridges within the GR generated by a variety of oxidizing agents (27). Cytosols made in this fashion were measured for steroid-binding capacities, and the results demonstrate that DlT was not capable of reversing the inhibitory effects of POBA on GR steroid-binding function. Although these results indicate that sulfhydryl oxidation is not the mechanism by which POBA inhibits GR steroid-binding function, the possibility still remains that POBA-induced sulfhydry oxidation is occurring and that it leads to GR misfolding that cannot be corrected by reducing agents acting under energy-deficient (4 C) conditions. Interestingly, hormone-binding capacity was unaffected when cytosol from untreated LMCAT cells was directly treated with POBA (Fig. 4C) . The latter result has two important implications.
First, the inability of POBA to inhibit steroid-binding under in vitro conditions eliminates the possibility that the actions of POBA are due to a competitive antagonism at the hormone-binding site of the GR. Second, the ineffectiveness of POBA in vitro suggests that its actions in viva are to inhibit a dynamic equilibrium within the intact cell that is responsible for either the maintenance or the generation of the hormone-binding competent GR.
The results of saturation hormone binding experiments are presented in Fig. 5 Although little is known about the intracellular processes that control the hormone-binding functions of the GR, there were two alternative posslbllltles that could be tested to explain the inhibitory effects of POBA on GR hormone-binding function. One possibility was that POBA treatment of the LMCAT cells was somehow promoting GR turnover, resulting in a decrease in GR protein levels. However, the results presented in Fig. 3 clearly show that the amount of GR protein in cytosols derived from POBA-treated cells is unchanged compared with that in control cell?., proving that the loss of GR hormone-binding function in response to POBA is not due to the loss of GR protein.
The second possibility was that GR levels remained unchanged, but that POBA treatment resulted in a structure/function change in the GR or GR complex components.
Given the large body of in vitro evidence for the role of hsp90 in maintaining the GR in the hormone-binding competent state (3-8), we reasoned that this structural change in the GR could take the form of a destabilization of the GR-hsp90 complex. To test this possibility, we performed the experiments shown in Fig. 6 , in which levels of GR-associated hsp90 were measured in cells treated with or without POBA. To our surprise, the amount of GR-associated hsp90 was also unchanged in the POBA-treated cells, suggesting that the CaM antagonist was not acting by causing a loss of hsp90 from the untransformed GR complex or by preventing association of hsp90 with GR during in viva assembly.
The anti-hsp90 serum used for probing of the Western blots in the experiment presented in Fig. 6 recognizes hsp70 in addition to hsp90. In keeping with our prior experience with the GR complex of L929 cells (29), very little, if any, hsp70 was found specifically bound to the untransformed GR complex, and the amount of GR-bound hsp70 did not change in response to POBA treatment (quantitative data not shown). We have also analyzed these samples for the presence of GR-associated hsp56 using a polyclonal antibody, but no change in the GR-hsp56 ratio was observed after POBA treatment (Fig. 6) three known steroid receptor-associated hsp: hsp90, hsp70, and hsp56.
DISCUSSION
We have provided evidence that the CaM antagonist POBA can efficiently inactivate the GR signal pathway in intact cells by a process that ultimately results in the loss of GR hormone-binding function. This decrease in hormone-binding function in response to POBA was not due to reductions in the amount of GR protein or receptor-associated hsp (hsp90, hsp70, and hsp56). Thus, by these criteria, the hormone-incompetent GR complex of POBA-treated cells appears be no different than the native untransformed complex of normal cells. What, then, can account for the loss of GR function within this complex? Clearly, we do not have the answer to this question at present, but a variety of intriguing possibilities exist. First, it is possible that the GR complex of POBAtreated cells has changed with respect to components other than hsp90, hsp70, and hsp56. In addition to these hsp, a variety of other proteins have recently been shown to associate with steroid receptor complexes (for review, see Ref. 30). These include FKBP54, an immunophilin that, like FKBP59 (hsp56), can bind the immunosuppressive drugs FK506 and rapamycin (31); CyP-40, an immunophilin that binds cyclosporin A (32); ~23, a unique acidic phosphoprotein (33); and ~60, a protein that, along with hsp70, transiently associates with PR complexes during assembly (34). In theory, then, the effects of POBA on GR function could be due to changes in content for any of these proteins within the untransformed GR complex, and further studies on the macromolecular state of the POBA-generated, hormone-incompetent GR will be required to answer this question.
A second explanation for the effects of POBA on GR function derives from the idea that some of the receptor-associated proteins denoted above may be involved in the folding and assembly of functional steroid receptor complexes.
All of these proteins, in addition to hsp70 and hsp56, have been shown to form complexes with hsp90 that are independent of [3H]Triamcinolone Acetonide (nM) steroid receptors, and the roles of these protein complexes in steroid receptor assembly have been extensively studied by the laboratories of Toti, Smith, and Pratt. A major common advancement from the work of these laboratories is the conclusion that hsp90 binding to receptors is required for the generation of functional (hormone-competent) steroid receptors, but that this process requires the participation of a variety of factors, some of which are the proteins denoted above. . using an expression system in baculovirusinfected insect cells, tested a series of hsp90 deletion mutants, some of which formed complexes with GR that were unable to bind hormone.
Bohen and Yamamoto (40) showed that point mutations of hsp90 could be generated which, when expressed in yeast, resulted in loss of GR signaling. Moreover, all of the hsp90 mutants retained their ability to interact with the untransformed GR, but failed to generate GR capable of efficient hormone-binding function. These two studies thus provided the first evidence that hsp90 involvement in the generation of hormone-competent receptors is more complicated than simple target recognition.
Both of these works relied on exogenous expression of GR and hsp90 in cells of lower eukaryotic organisms, the results of which could be questioned due to the potential for artifact in exotic expression systems. In our study, we have found further evidence for this dual role of hsp90 in a mammalian cell line and for endogenous gene products. Most importantly, these results reinforce the hypothesis that hsp90. either alone or in concert with other GR-associated proteins, plays an active role in the mainte-VollONo.1 20 nance of receptors capable of high affinity ligand binding.
Given the recent evidence that both free (16, 17) and GR-associated hsp90 (25) can bind CaM under in vitro conditions, it is interesting to speculate that the alteration in GR function reported here in response to POBA treatment could be due to a lack of CaM interaction with hsp90 either before or after it becomes bound to the GR. In support of this idea is our observation that Ca*'--dependent binding to CaM by both hsp90 and untransformed GR complexes can be inhibited by POBA as well as several other CaM antagonists (unpublished observations). However, other potential targets for CaM action on the GR signal pathway exist. For example, members of both the hsp56 and hsp70 protein families have been shown to contain highly conserved CaM-binding domains and to bind CaM in a Cazi -dependent manner (17, 41-43). As hsp70 plays an important role in the folding and assembly of mature steroid receptor complexes (44), an alteration of hsp70 function due to lack of CaM interaction could be responsible for the results reported here. In the case of hsp56, both the rabbit and human forms of this protein have been shown to contain consensus CaM kinase phosphorylation sites (45, 46) and its phosphorylation in vitro can be inhibited by the CaM antagonist calmidzolium (47). These observations present the intriguing possibility that the role, if any, of hsp56 in GR steroid-binding function may be regulated by CaM-dependent phosphorylation mechanisms.
As detailed in the introduction, a variety of reports exist providing evidence for the involvement of CaM in steroid receptor-mediated signaling. In two of these reports, a connection between glucocor-ticoid-mediated apoptosis and CaM was demonstrated (23, 24), and in each case, steroid-induced apoptosis was inhibited by CaM antagonists.
A logical conclusion of these findings is that the CaM antagonists act to block the apoptotic actions of glucocorticoids by inhibiting CaM, whose synthesis is at least partially controlled by the GR (24). However, in light of our results, it must now be considered that CaM antagonism may also serve to inhibit glucocot-ticoid-mediated apoptosis by blocking activation of the GR signal pathway. Thus, it is possible that CaM antagonists act on two fronts to block steroid-induced cell death: 1) by direct inhibition of CaM as a mediator of apoptosis, and 2) by lowering CaM proteins levels via an inhibition of GR-mediated expression of the CaM gene. Of course, our observations also present the possibility that inhibition of GR activation by CaM antagonists could lead to decreases in expression of GR-regulated gene products, other than CaM, some of which may also be involved in apoptosis.
Although our results, using the CaM antagonist POBA, do not by themselves provide proof for the involvement of CaM in the maintenance or generation of the untransformed, hormone-competent state of the GR, they do provide strong evidence to this effect.
Antagonists such as POBA have been widely used in the molecular analyses of CaM actions (see Refs. 48 and 49 for review). One possible drawback of the use of CaM antagonists is their potential for interaction with targets other than CaM. POBA, for example, was originally developed as an adrenergic antagonist, but it is unlikely that the effects of POBA described herein are via this mechanism, as we have not been able to prevent the POBA inhibition of GR activation with the adrenergic agonist norepinephrine (data not shown). In a prior study, we tested the effects of several, structurally unrelated antagonists (POBA, trifluoperazine, compound 48/80, and the naphthalenesulfonamide, W7) on Dex-induced GR transactivation, and each compound inhibited this process to varying degrees (25). As each of these compounds have different nonCaM side targets, their common actions on the GR signal pathway are a strong indication that these actions are mediated by a common target protein, namely CaM. Although proof of CaM involvement in the GR signal pathway awaits the development of the appropriate molecular approaches, our results nonetheless demonstrate the utility of phenoxybenzamine in identifying a novel stage of the GR signal pathway within intact cells, a stage in which the receptor is still complexed to hsp90 but can no longer bind hormone. Whether this stage of the GR represents a step in the assembly of hormone-competent GR after de nova synthesis, in the reassembly of GR after nuclear shuttling, or in a novel inactivation pathway remains to be determined. Cytosol Preparation, Cellular Fractionation, and lmmunoadsorption of GR
MATERIALS AND METHODS

Materials
In the experiments presented in Fig. 6 , cytosols were prepared by Dounce A (Kontes Co., Vineland, NJ) homogenization of LMCAT cells in hypotonic buffer (10 mM HEPES, 3 mM EDTA, and 10 mM sodium molybdate, pH 7.4) followed by centrifugation at 13,600 x g. In the experiments shown in Fig.  3 , LMCAT cells were fractionated into cytosolic and nuclear portions by Dounce A homogenization in hypotonic buffer, followed by centrifugation at 1,000 x g. The cytosolic fractions were saved, and the nuclear pellets were washed twice by resuspension and pelleting in hypotonic buffer. Hypotonic buffer was then added to both the pellet and cytosolic fractions to a final volume of 0.5 ml. Each fraction was made 0.5 M for NaCl by the addition of 0.5 ml of a 1 -M stock solution in TEG (10 mM TES, 1 mM EDTA, 10% glycerol, 50 mM NaCI, and 10 mM sodium molybdate, pH 7.6) and incubated on ice with occasional vortexing for 1 h. After salt extraction, the nuclear pellets were centrifuged at 13,600 x g, and the supernatants were saved.
For the experiments shown in Figs. 3 
Steroid Binding Assay
In the experiments depicted in Fig. 4 
